Comparative Pharmacology
Head-to-head clinical analysis: LOGILIA versus NORCEPT E 1 35 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOGILIA versus NORCEPT E 1 35 28.
LOGILIA vs NORCEPT-E 1/35 28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lorecivivt, the active component of Logilia, is a small interfering RNA (siRNA) that targets the synthesis of transthyretin (TTR) protein. It binds to a genetically conserved sequence in the 3' untranslated region of mutant and wild-type TTR mRNA, leading to its degradation via RNA interference. This reduces TTR protein production and deposition in tissues.
Combination estrogen (ethinyl estradiol) and progestin (norethindrone) contraceptive: suppresses gonadotropin release, inhibits ovulation, thickens cervical mucus, and alters endometrial lining.
100 mg orally once daily.
1 tablet orally once daily for 21 days, followed by 7 days of placebo tablets.
None Documented
None Documented
Terminal elimination half-life: 12–15 hours; dose adjustment recommended in renal impairment
Norethindrone: 5-14 hours; ethinyl estradiol: 13-27 hours. The terminal half-life of norethindrone is about 10 hours, allowing once-daily dosing; ethinyl estradiol's longer half-life contributes to steady-state concentrations within 3-5 days.
Approximately 60% renal (as unchanged drug), 40% biliary/fecal
Renal (primarily as metabolites) and fecal; approximately 50-60% excreted in urine, 30-40% in feces. Ethinyl estradiol and norethindrone are extensively metabolized via hydroxylation and conjugation; glucuronide and sulfate conjugates are eliminated in urine and bile.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive